Andrew Tsai
Stock Analyst at Jefferies
(2.29)
# 2,629
Out of 5,114 analysts
29
Total ratings
52.17%
Success rate
-1.67%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.78 | +15.71% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $33.80 | -11.24% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $272.92 | +64.88% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $20.55 | +55.72% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $19.98 | +25.13% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.47 | -6.85% | 1 | Oct 22, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $174.80 | +8.70% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $21.04 | +66.35% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $31.96 | -6.13% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $76.30 | -8.26% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.23 | -22.60% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $152.65 | +31.02% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $16.00 | +68.75% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.35 | +198.85% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $30.85 | +13.45% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.17 | +156.41% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $6.97 | +330.42% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.96 | +581.82% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $44.10 | -47.85% | 1 | Jun 1, 2020 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.78
Upside: +15.71%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $33.80
Upside: -11.24%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $272.92
Upside: +64.88%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $20.55
Upside: +55.72%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $19.98
Upside: +25.13%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.47
Upside: -6.85%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $174.80
Upside: +8.70%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $21.04
Upside: +66.35%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $31.96
Upside: -6.13%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $76.30
Upside: -8.26%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.23
Upside: -22.60%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $152.65
Upside: +31.02%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $16.00
Upside: +68.75%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.35
Upside: +198.85%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $30.85
Upside: +13.45%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.17
Upside: +156.41%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $6.97
Upside: +330.42%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.96
Upside: +581.82%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $44.10
Upside: -47.85%